Women's Hormonal Health & Endocrine Wellness: The Complete UK Guide

The endocrine system is a network of glands distributed throughout the body — including the ovaries, thyroid, adrenal glands, pituitary, and pancreas — each producing chemical messengers known as hormones. These hormones travel through the bloodstream and deliver instructions to organs and tissues, regulating everything from your metabolic rate and reproductive function to your stress response and bone density.

In women, the endocrine system is particularly dynamic. Hormonal concentrations shift across the monthly cycle, across decades of reproductive life, and through the significant physiological transition of menopause. Understanding these shifts — and detecting when they deviate from healthy norms — is the foundation of modern women's preventative healthcare.

Private blood testing makes this understanding actionable. Rather than waiting for symptoms to become severe enough to prompt a GP visit, regular hormonal profiling allows women to identify imbalances early, track trends over time, and take clinically informed steps to restore and maintain balance.

The menstrual cycle is far more than a monthly biological inconvenience. It is one of the body's most sensitive barometers of overall hormonal health. The NHS describes the average cycle as spanning approximately 28 days, though significant variation exists — and deviation from 28 days is not inherently abnormal.

The cycle is governed by a tightly orchestrated sequence of four hormonal phases.

The hormonal drop in the late luteal phase is the primary driver of premenstrual syndrome (PMS). When symptoms are severe and cyclically debilitating, the condition is classified as Premenstrual Dysphoric Disorder (PMDD) — a diagnosable clinical condition responsive to both lifestyle and pharmacological intervention when properly identified.

While cycle-to-cycle variation is normal, significant and persistent irregularity warrants investigation. Several well-evidenced factors are known to disrupt the hormonal signalling that regulates the cycle.

Psychological and physical stress

Chronic psychological stress activates the hypothalamic-pituitary-adrenal (HPA) axis, elevating cortisol and suppressing the pulsatile release of GnRH — the master reproductive hormone — which in turn disrupts FSH and LH secretion. Higher perceived stress correlates with increased rates of cycle disruption, dysmenorrhoea, and premenstrual symptoms.

Energy deficiency

Inadequate caloric intake relative to energy expenditure — whether through dieting, disordered eating, or intensive athletic training — suppresses reproductive hormone output and can result in menstrual irregularity, amenorrhoea, and long-term consequences for bone health. This mechanism is not limited to athletes; any significant caloric deficit can produce similar hormonal suppression.

Medications

Certain prescribed medications are documented to affect menstrual regularity. Antidepressant use — particularly serotonin reuptake inhibitors — has been associated with cycle irregularity, menorrhagia, and amenorrhoea. Some cardiac medications can also affect menstrual bleeding. Women experiencing new or worsening irregularity after starting any medication should discuss this with their prescribing clinician.

Understanding why your cycle is disrupted — not just that it is disrupted — requires targeted investigation. A comprehensive hormonal blood panel, interpreted alongside a detailed clinical history, provides the most diagnostically useful picture.

Polycystic Ovary Syndrome (PCOS) is one of the most prevalent endocrine disorders affecting women of reproductive age, with an estimated global prevalence of 6–13% depending on diagnostic criteria. Despite its prevalence, it remains significantly underdiagnosed, with many women waiting years between symptom onset and formal diagnosis.

What causes PCOS?

PCOS is characterised by excess androgen production. Elevated androgens disrupt the normal maturation and release of eggs, causing follicles to accumulate in the ovaries rather than completing ovulation. Insulin resistance plays a central mechanistic role: excess circulating insulin stimulates the ovaries to produce additional androgens, creating a self-reinforcing cycle of hormonal disruption with significant long-term metabolic implications.

Recognising the symptoms

PCOS presents differently across individuals, which is one reason it is so frequently missed. Common features include:

• Irregular or absent periods — the most universal indicator of disrupted ovulation
• Excess hair growth (hirsutism) — typically on the face, chest, or abdomen
• Acne and oily skin — particularly when persistent beyond adolescence
• Scalp hair thinning — androgenic alopecia in a female pattern
• Difficulty losing weight or unexplained weight gain — often linked to insulin resistance
• Difficulty conceiving — due to irregular or absent ovulation

Diagnosis is defined by the Rotterdam Criteria, which require at least two of: irregular or absent ovulation, clinical or biochemical evidence of elevated androgens, and polycystic ovarian morphology on ultrasound. A blood panel is an essential component of the diagnostic workup, not a replacement for clinical assessment.

How private blood testing identifies PCOS

Early identification through blood testing enables timely dietary, lifestyle, and clinical interventions that can significantly reduce the long-term metabolic and reproductive consequences of PCOS.

Menopause marks the point at which a woman has experienced 12 consecutive months without a menstrual period — the permanent end of ovarian reproductive function. In the UK, this typically occurs between the ages of 45 and 55. However, the hormonal transition begins considerably earlier in perimenopause — often the most challenging phase to navigate without clinical guidance.

The hormonal landscape of perimenopause

During perimenopause, the ovaries produce oestrogen in an increasingly erratic pattern. This hormonal volatility — rather than simple oestrogen decline — drives many of the most disruptive symptoms:

• Vasomotor symptoms — hot flushes and night sweats
• Sleep disturbance — difficulty initiating sleep and early waking
• Mood changes — anxiety, low mood, and emotional reactivity
• Cognitive changes — memory lapses and reduced concentration ("brain fog")
• Genitourinary symptoms — vaginal dryness, urinary urgency, and increased UTI susceptibility
• Skin and musculoskeletal changes — reduced elasticity, joint aches, and hair thinning

Blood testing for perimenopause

Perimenopause is primarily a clinical diagnosis, but blood testing provides important supporting evidence — particularly in women under 45. Key markers include FSH (consistently elevated above 30 IU/L on two tests at least six weeks apart supports diagnosis when interpreted with symptoms), oestradiol, and AMH as an early signal of declining ovarian reserve.

Long-term health implications of oestrogen decline

Oestrogen plays a protective role in cardiovascular health, bone mineral density, and cognitive function. Following menopause, cardiovascular risk increases significantly and bone mineral density declines at an accelerated rate. Regular blood testing — including bone turnover markers, lipid profiles, inflammatory markers, and hormonal panels — provides the data needed to monitor and mitigate these risks.

The thyroid gland regulates metabolic rate, cardiovascular function, body temperature, mood, and reproductive health. Women are disproportionately affected by thyroid disorders — hypothyroidism affects approximately 2% of women, with a further estimated 5% having subclinical hypothyroidism. Symptoms overlap substantially with depression, anaemia, perimenopause, and anxiety, contributing to frequent diagnostic delay.

Hypothyroidism (underactive thyroid)

• Persistent fatigue and low energy despite adequate sleep
• Unexplained weight gain or difficulty losing weight
• Feeling cold, particularly in the extremities
• Dry skin, brittle nails, and hair loss
• Cognitive slowing, poor memory, and low mood
• Constipation and slowed digestive function
• Menstrual irregularity — often heavy or prolonged periods

The most common cause in the UK is Hashimoto's thyroiditis. Thyroid antibodies (TPOAb and TgAb) can be elevated for years before TSH becomes abnormal — meaning antibody testing is essential for early detection yet is frequently omitted from standard NHS panels.

Hyperthyroidism (overactive thyroid)

• Unexplained weight loss despite normal or increased appetite
• Palpitations, racing heart, or irregular heartbeat
• Anxiety, tremor, and heightened emotional reactivity
• Excessive sweating and heat intolerance
• Disrupted sleep and paradoxical fatigue
• Increased bowel frequency
• Menstrual cycle irregularity — often lighter or absent periods

The most common cause is Graves' disease. TSH receptor antibodies (TRAb) are a specific marker for this diagnosis.

Why standard thyroid testing is often insufficient

NHS standard thyroid testing typically measures TSH alone. While TSH is an important marker, it does not provide a complete picture — particularly for women whose TSH falls within the reference range but symptoms persist.

The adrenal glands produce cortisol, DHEA-S, and adrenaline — hormones with significant influence on energy, mood, weight regulation, immune function, and broader hormonal balance.

Cortisol and the HPA axis

Acute cortisol release is a healthy survival mechanism. In sustained stress, chronic cortisol elevation can disrupt sleep, promote visceral fat accumulation, suppress immune competence, and interfere with reproductive hormone balance — cortisol competes with progesterone at receptor level, and chronically elevated cortisol can suppress the LH surge necessary for ovulation.

Chronically elevated cortisol also impairs the peripheral conversion of T4 to active T3, potentially contributing to hypothyroid-like symptoms even when standard thyroid function tests appear normal.

DHEA-S and adrenal reserve

DHEA-S is a marker of adrenal reserve that declines with age and can fall sharply in response to chronic stress. In women, DHEA-S contributes to peripheral production of oestrogen and testosterone. Measuring DHEA-S alongside cortisol provides a more clinically complete picture of adrenal function than either marker in isolation.

The table below summarises the core hormonal biomarkers included in a comprehensive women's health blood panel, together with what each marker reveals and why it matters clinically.

1. 1.Boardman, H. M., et al. (2015). Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews.
2. 2.Bozdag, G., et al. (2016). The prevalence and phenotypic features of polycystic ovary syndrome. Human Reproduction.
3. 3.British Heart Foundation. (2023). Heavy periods when you're on heart medication.
4. 4.Bull, J. R., et al. (2019). Real-world menstrual cycle characteristics of more than 600,000 menstrual cycles. npj Digital Medicine.
5. 5.Cabre, H. E., et al. (2022). Relative energy deficiency in sport (RED-S). Deutsche Zeitschrift für Sportmedizin.
6. 6.Cambridge University Hospitals NHS Foundation Trust. (2024). Menopause: A healthy lifestyle guide.
7. 7.Chaker, L., et al. (2017). Hypothyroidism. The Lancet.
8. 8.Morris, D. H., et al. (2010). Determinants of age at menarche in the UK. British Journal of Cancer.
9. 9.Nagma, S., et al. (2015). To evaluate the effect of perceived stress on menstrual function. Journal of Clinical and Diagnostic Research.
10. 10.National Institute for Health and Care Excellence. (2019). Menopause: Diagnosis and management (NG23).
11. 11.NHS. (2023a). Periods and fertility in the menstrual cycle.
12. 12.NHS. (2023b). Periods.
13. 13.Teede, H. J., et al. (2023). Recommendations from the 2023 international evidence-based guideline for PCOS. Journal of Clinical Endocrinology & Metabolism.
14. 14.Uguz, F., et al. (2012). Antidepressants and menstruation disorders in women. General Hospital Psychiatry.
15. 15.Vanderpump, M. P. J. (2011). The epidemiology of thyroid disease. British Medical Bulletin.
16. 16.World Health Organization. (2023). Polycystic ovary syndrome.